Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice

Fibrinolysis

Volumn 10, Issue 4, 1996, Pages 195-213

  Carmeliet, P ^a,b   Collen, D ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN;

ADENOVIRUS; BLOOD CLOTTING; CONFERENCE PAPER; FIBRINOLYSIS; GENE THERAPY; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS;

EID: 0029827894     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80017-8     Document Type: Conference Paper

References (131)

1. Edgington T S, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
2. Furie B, Furie B C. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
3. Davie E. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
4. Esmon C T. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-145.
5. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gin mutation in factor Va a pathogenic risk factor for thrombosis. Thromb Haemost 1995; 74: 139-148.
6. Bick R L, Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Seminars Thromb Hemost 1994; 20: 109-132.
7. Broze G J. Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Trends Cardiovasc Med 1992; 2: 72-77.
8. Hoyer L W. Hemophilia A. N Engl J Med 1996; 330: 38-47.
9. Bolton-Maggs P H B, Hill F G H. The rarer inherited coagulation disorders: a review. Blood Rev 1995; 9: 65-76.
10. Altieri D C. Xa receptor EPR-1. FASEB J 1995; 9: 860-865.
11. Coughlin S R. Molecular mechanisms of thrombin signaling. Semin Hematol 1994; 31: 270-277.
12. Astrup T. In: Davidson J F, Rowan R M, Samama M M, Desnoyers P C (eds). Progress in Chemical Fibrinolysis and Thrombolysis. Vol 3. Raven Press, New York, 1978; 1-57.
13. Collen D, Lijnen H R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124.
14. Vassalli J D, Sappino J D, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072.
15. Schneiderman J, Loskutoff D J. Plasminogen activator inhibitors. Trends Cardiovasc Med 1991; 1: 99-102.
16. Wiman B. Plasminogen activator inhibitor 1 in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-76.
17. Lawrence D A, Ginsburg D. In: High K A, Roberts H R (eds) Plasminogen Activator Inhibitors. Dekker, New York, 256: 517-543.
18. Bachmann F. The engima of PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemost 1995; 74: 172-179.
19. Martin T J, Allan E H, Fukumoto S. The plasminogen activator and inhibitor system in bone remodeling. Growth Regulation 1993; 3: 209-214.
20. Hajjar K A. Cellular receptors in the regulation of plasmin generation. Thromb Haemost 1995; 74: 294-301.
21. Plow E F, Herren T, Redlitz A, Miles L A, Hoover-Plow J L. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-945.
22. Vassalli J D. The urokinase receptor. Fibrinolysis 1994; 8 (Suppl 1): 172-181.
23. Blasi F, Conese M, Moller L B, Pedersen N, Cavallaro U, Cubellis M V, Fazioli F, Hernandez-Marrero L, Limongi P, Munoz-Canoves P, Resnati M, Rüttininen L, Sidenius N, Soravia E, Soria M R, Stoppelli M P, Talarico D, Teesalu T, Valcamonica S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis, 1994; 8 (Suppl 1): 182-188.
24. Dano K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase-receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 1994; 8 (Suppl 1): 189-203.
25. Wei Y, Waltz I) A, Rao N, Drummond R J, Rosenberg S, Chapman H A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
26. Saksela O, Rifkin D. Cell-associated plasminogen activation: regulation and physiological functions. A Rev Cell Biol 1988; 4: 93-126.
27. Andreasen P A, Sottrup-Jensen Ll et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Letters 1994; 338: 239-245.
28. Capecchi M. R. Targeted gene replacement. Sci Am 1994; 34-41.
29. Nagy A. Engineering the mouse genome. Methods Enzymol (in press).
30. Nagy A, Rossant J. Targeted mutagenesis: analysis of phenotype without germline transmission. J Clin Invest 1996; 6: 1360-1365.
31. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq G, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
32. Mulligan R C M The basic science of gene therapy. Science 1993; 260: 926-932.
33. Schneider M D, French B A. The advent of adenovirus: gene therapy for cardiovascular disease. Circulation 1995; 88: 1937-1942.
34. Carmeliet P, Stassen J M, Collen D, Meidell R, Gerard R. Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice (submitted).
35. Soifer S J, Peters K G, O'Keefe J, Coughlin S R. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol 1994; 144: 60-69.
36. Luther T, Flössel C, Mackman N, Bierhaus A, Kasper M, Albrecht S, Sage H A, Iruela-Arispe L, Grossman H, Ströhlein A, Zhang Y, Nawroth P P, Carmeliet P, Loskytoff D J, Müller M. Tissue factor expression during human and mouse development. Am J Pathol (1996; in press).
37. Imada S, Yamaguchi H, Nagumo N, Katyanagi S, Iwasaki H, Imada M. Identification of fetomodulin, a surface marker protein of fetal development as thrombomodulin by gene cloning and functional assays. Dev Biol 1990; 140: 113-122.
38. Healy A, Rayburn H, Rosenberg R, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995; 92: 850-854.
39. Carmeliet P, Mackman N, Moons L, Wyns S, Van Vlaenderen I, Luther T, Breier G, Lissens A, Rosen E, Mu7̈ller M, Risau W, Edgington T, Collen D. Role of the cellular receptor tissue factor in embryonic vessel development (submitted).
40. Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
41. Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern D M, Nawroth P P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-1327.
42. Contrino J, Hair G, Kreutzer D L, Rickles F R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Medicine 1996; 2: 209-215.
43. Suh T T, Holmbäck K, Jensen N J, Daugherty C C, Small K, Simon D I, Potter S S, Degen J L. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen deficient mice. Genes Dev 1995; 9: 2020-2033.
44. Erickson L A, Fici G J, Lund J E, Boyle T P, Polites H G, Marotti K R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76.
45. Eitzman D T, McCoy R D, Zheng X, Fay W P, Shen T, Ginsburg D. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237.
46. Heckel J L, Sandgren E P, Degen J L, Palmiter R D, Brinster R L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-456.
47. Sidenius N. Expression of the aminoterminal fragment of urokinase-type plasminogen activator in transgenic mice. PhD thesis, University of Copenhagen, Denmark, 1993.
48. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord J J, Collen D, Mulligan R. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.
49. Carmeliet P, De Clercq C, Janssen S, Pollefeyt S, Bouché A, Wijns S, Mulligan R C, Collen D. Biological effects of disruption of the tissue-type plasminogen activator, urokinasetype plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 1995; 748P: 367-381.
50. Bugge T H, Flick M J, Danton M J, Daugherty C C, Romer J, Dano K, Carmeliet P, Collen D, Degen J L. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA (in press).
51. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan R C. Plasminogen activator inhibitor-1 gene deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-2755.
52. Carmeliet P, Stassen J M, Schoonjans L, Ream B, van den Oord J J, De Mol M, Mulligan R C, Collen D. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
53. Dewerchin M, Van Nuffelen, Wallays G, Bouché A, Moons L, Carmeliet P, Mulligan R C M, Collen D. Generation and characterization of urokinase receptor deficient mice. J Clin Invest 1996; 97: 870-878.
54. Bugge T H, Suh T T, Flick M J, Daugherty C C, Romer J, Solberg H, Ellis V, Dano K, Degen J L. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 1995; 270: 16886-16894.
55. Ploplis V, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow E, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth and health in mice. Circulation 1995; 92: 2585-2593.
56. Bugge T H, Flick M J, Daugherty C C, Degen J L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.
57. Dougherty K, Yang A, Harris J, Saunders T, Camper S, Ginsburg D. Targeted deletion of the murine plasminogen activator inhibitor-2 gene by homologous recombination. Blood 1995; (Suppl I): 86: 455a.
58. Zheng X, Saunders T L, Camper S A, Samuelson L C, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 1995; 92: 12426-12430.
59. 2-macroglobulin gene. J Biol Chem 1995; 270: 19778-19785.
60. Herz J, Clouthier D E, Hammer R E. LDL receptor-related protein internalizes and degrades uPA:PAI-1 complexes and is essential for embryo implantation. Cell 1992; 71: 411-421.
61. Richards W G, Carroll P M, Kinloch R A, Wassarman P M, Strickland S. Creating maternal effect mutations in transgenic mice: antisense inhibition of an oocyte gene product. Dev Biol 1993; 160: 543-553.
62. Leonardsson G, Peng X R, Liu K, Nordström L, Carmeliet P, Mulligan R, Collen D, Ny T. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci USA 1995; 92: 12446-12500.
63. Cui J, Saunders T L, Ginsburg D. Analysis of factor V function by gene targeting in embryonic stem cells. Blood 1995; (Suppl I): 86: 449a.
64. Bi L, Lawler A M, Antonarakis S E, High K A, Gearhart J D, Kazazaian H H Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genetics 1995; 10: 119-121.
65. Montgomery R R, Scott J P. Hemostasis: diseases of the fluid phases. In: Nathan G D & Oski F A (eds) Haematology of infancy and childhood. Saunders WB Co, Philadelphia, PA. 1993: 1605-1650.
66. Al-Mondhiry H, Ehmann W C. Congenital afibrinogenemia. Am J Hematol 1994; 46: 343-347.
67. White G C. Coagulation factors V and VIII: normal function and clinical disorders. In: Handin R I, Lux S E, Stossel T P (eds) Blood. Principles & Practice of hematology. JB Lippincott Co, Philadelphia. 1995: 1151-1180.
68. Fay W P, Shapiro A D, Shih J L, Schleef R R, Ginsburg D. Complete deficiency of plasminogen-activator inhibitor type 1 due to a frameshift mutation. N Engl J Med 1992; 327: 1729-1733.
69. Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 1989; 3: 11-17.
70. Elliott M J, Faulkner-Jones B E, Stanton H, Hamilton J A, Metcalf D. Plasminogen activator in granulocyte-macrophageCSF transgenic mice. J Immunol 1992; 149: 3678-3681.
71. Kluft C, Dooijewaard G, Emeis J J. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50-68.
72. Plow E F, Edgington T S. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 1975; 56: 30-38.
73. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
74. Robbins K C. Dysplasminogenemias. Enzyme 1988; 40: 70-78.
75. Liu A C, Lawn R M. Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med 1994; 4: 40-44.
76. Palabrica T M, Liu A C, Aronowitz M J, Furie B, Lawn R M, Furie B C. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Medicine 1995; 1: 256-259.
77. Forrester J S, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-769.
78. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton S K. A cascade model for restenosis. A special case of atherosclerotic progression. Circulation 1992; 86 (Suppl III): 47-52.
79. Clowes A W, Reidy M A. Prevention of stenosis after vascular reconstruction: pharmacologic control of intima hyperplasia -A review. J Vasc Surg 1991; 13: 885-891.
80. Simpson A J, Booth N A, Moore N R, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143.
81. Clowes A W, Clowes M M, An Y P T, Reidy M A, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67.
82. Jackson C L, Reidy M A. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci 1992; 667: 141-150.
83. Jackson C L, Raines E W, Ross R, Reidy M A. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscl Thromb 1993; 13: 1218-1226.
84. Sawa H, Fujii S, Sobel B E. Augmented arterial wall expression of type-1 plasminogen activator induced by thrombosis. Arterioscler Thromb 1992; 12: 1507-1515.
85. Carmeliet P, Collen D. Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice. In: Vadas M and Harlan J (eds) Vascular control of hemostasis; Advances of Vascular Biology (in press).
86. Herbert J M, Lamarche I, Prabonnaud V, Dol F, Gauthier T. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 1994; 269: 3076-3080.
87. Carmeliet P, Stassen J M, Declercq C, Kockx M, Moons L, Collen D. A model for arterial neointima formation using perivascular electric injury in mice (submitted).
88. Carmeliet P, Moons L, Dewerchin M, Stassen J M, Declercq C, Gerard R, Collen D. Receptor-independent role of urokinasetype plasminogen activator in arterial neointima formation in mice (submitted).
89. Carmeliet P, Moons L, Van Vlaenderen I, Ploplis V, Plow E F, Collen D. Role of plasmin proteolysis in arterial neointima formation in mice (submitted).
90. Yu H R, Schultz R M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990; 50: 7623-7633.
91. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator. Inhibition of proliferation and invasion of human ovarian cancer cells. FEES Lett, 1994; 337: 131-134.
92. Lee S W, Kahn M L, Dichek D A. Expression of an anchored urokinase in the apical endothelial cell membrane. J Biol Chem 1992; 267: 13020-13029.
93. Stephens R W, Bokman A M, Myöhänen H T, Reisberg T, Tapiovaara H, Pedersen N, Grondahl-Hansen J, Llinas M, Vaheri A. Heparin binding to the urokinase kringle domain. Biochemistry 1992; 31: 7572-7579.
94. Hamsten A, Eriksson P. Fibrinolysis and Atherosclerosis: an update. Fibrinolysis 1994; 8 (Suppl 1): 253-262.
95. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-438.
96. Schneiderman J, Sawdey M S, Keeton M R, Bordin G M, Bernstein E F, Dilley R B, Loskutoff D J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
97. Schneiderman J, Bordin G M, Engelberg I, Adar R, Seiffert D, Thinnes T, Bernstein E F, Dilley R B, Loskutoff D J. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechaism for aneurysm expansion. J Clin Invest 1995; 96: 639-645.
98. Lupu F, Heim D A, Bachmann F, Hurni M, Kakkar V V, Kruithof E K O. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb 1995; 15: 1444-1455.
99. Grainger D J, Kemp P R, Liu A C, Lawn R M, Metcalfe J M. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-462.
100. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapoli W, Chapman H A. Depressed bronchioalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322: 890-897.
101. Tomooka S, Border W A, Marshall B C, Nobel N A. Glomerular matrix accumulation in liked to inhibition of the plasmin protease system. Kidney Int 1992; 42: 1462-1469.
102. Kitching R, Carmeliet P, Ploplis V, Collen D, Plow E, Holdsworth E R, Tipping P. Glomerulonephritis in mice with genetic deficiencies of the plasminogen system. XIIIth International Congress on Fibrinolysis and thrombolysis, Barcleona, June 24-28, 1996.
103. Barazzone C, Belin D, Huarte J, Vassalli J D, Sappino A P. Deleterious role of plasminogen activator inhibitor-1 in response to hyperoxia in mouse. 1996 International Conference, New Orleans, Louisiana.
104. Romer J, Bugge T H, Pyke C, Lund L R, Flick M J, Degen J L, Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Medicine 1996; 2: 287-292.
105. Leloup G, Lemoine P, Carmeliet P, Vaes G. Bone resorption and response to parathyroid hormone or 1,25 dihyroxyvitamin D3 in fetal metatarsals and calvariae from transgenic mice devoid of tissue or urokinase type plasminogen activator or of their inhibitor, PAI-1. Twenty fourth European Symposium on Calcined Tissues. Aarhus, Denmark, May 1995.
106. Bouillon R, Van Herck E, Verhaeghe J, Carmeliet P. Bone metabolism in transgenic mice, deficient in tissue type plasminogen activator. Xth International Congress on Calcium regulatory hormones, Melbourne, Australia, February 1995.
107. Sitrin R G, Shollenberger S B, Stricter R M, Gyetko M R. Endogenously produced urokinase activity amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes. J Leukoc Biol (1996; in press).
108. Matsushima K, Taguchi M, Kovacs E J, Yound H A, Oppenheim J J. Intracellular localization of human monocytic interleukin-1 (IL-1) activity and release of biologically IL-1 from monocytes by trypsin and plasmin. J Immunol 1986; 136: 2883-2891.
109. Auberger P, Sonthonnax S, Peyron J F, Mari B, Fehlmann M. A chymotryptic-type serine proteinase is required for IL-2 production by Jurkat T cells. Immunology 1993; 70: 547-550.
110. Gyetko M R, Chen G H, McDonald R A, Goodman R, Huffnagle G B, Wilkinson C C, Fuller J A, Toews G B. Urokinase is required for the pulmonary inflammatory response to cryptococcus neoformans (in press).
111. Tacchini-Cottier F, Vesin C, Philippeaux M M, Belin D, Vassalli P, Piguet P F. Tumor necrosis factor induces platelet activation and consumption in vivo, a process involving urokinase-type plasminogen activator and plasminogen. Abstr. 6th Interntl TNF Congress, Rhodes, Hellas. May 8-12, 1996.
112. Menoud P A, Debrot S, Schowing J. Roux's Arch Devel Biol 1989; 198: 219-226.
113. Qian Z, Gilbert M E, Colicos M A, Kandel E R, Kuhl D. Tissue-type plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361: 453-457.
114. Sappino A P, Madani R, Huarte J, Belin D, Kiss J Z, Wohlwend A, Vassalli J D. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92: 679-685.
115. Krystosek A, Seeds N W. Plasminogen activator release at the neuronal growth cone. Science 1981; 213: 1532-1534.
116. Carroll P M, Tsirka S, Richards W G, Frohman M A, Strickland S. Promoter sequences of the tissue-type plasminogen activator gene are able to confer tissue-specific expression of LacZ during mouse development (in press).
117. Theuring F, Aguzzi A, Turner J D, Kropp C, Wohn K D, Hoffmann S, Schleuning W D. Analysis of human tissue-type plasminogen activator gene promoter activity during embryogenesis of transgenic mice and rats and its induction in the adult mouse brain (submitted).
118. Meiri N, Masos T, Rosenblum K, Miskin R, Dudai Y. Overexpression of urokinase-type plasminogen activator in transgenic mice is correlated with impaired learning. Proc Natl Acad Sci USA 1994; 91: 3196-3200.
119. Huang Y Y, Bach M E, Wolfer D P, Zhuo M, Lipp H P, Hawkins R D, Schoonjans L, Godfraiend J M, Kandel E R, Mulligan R C, Collen D, Carmeliet P. Selective interference with a late stage of both Schaffer collateral and mossy fiber long term potentiation in mice lacking the gene encoding tissue-type plasminogen activator (submitted).
120. Frey U, Müller M, Kühl D. A different form of long-lasting potentiation revealed in tissue plasminogen activator mutant mice. J Neurosci 1996; 16: 2057-2063.
121. Tsirka S E, Gualandris A, Amaral D G, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-344.
122. Seeds N W, Haffke S, Christensen K, Schoonmaker J. Cerebellar granule cell migration involves proteolysis. In: Lander J M (ed) Molecular aspects of development and aging of the nervous system. Plenum Press, NY. 1990; 169-178.
123. Nakajima K, Reddington M, Kohsaka S, Kreutzberg G W. Induction of urokinase-type plasminogen activator in rat facial nucleus by axotomy of the facial nerve. J Neurochem 1996; 66 (in press).
124. Reddington M, Haas C, Kreutzberg G W. The plasminogen activator system in neurons and glia during motorneuron regeneration. Neuropathol Appl Neurobiol 1994; 20: 188-190.
125. 125I-tissue type plasminogen activator binding to cerebellar granule neurons. J Cell Biol 1989; 109: 265-271.
126. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17: 303-312.
127. Poggi A, Bellelli E, Carmela R, Castelli M P, Salvatore L, Marinacci R, Erickson L A, Benedetta Donati M, Bini A. Reduced pulmonary metastases of Lewis Lung Carcinoma in mice transgenic for the plasminogen activator inhibitor-1 gene (submitted).
128. Ploplis V, French E, Carmeliet P, Collen D, Plow E. The plasminogen system and cell migration during an inflammatory response. XIIIth International Congress on Fibrinolysis and thrombolysis, Barcelona, June 24-28, 1996.
129. Wagner E F. On transferring genes into stem cells and mice. Embo J 1990; 9: 3024-3032.
130. Botteri F M, Van der Putten H, Rajput B, Ballmer-Hofer K, Nagamine Y. Induction of the urokinase-type plasminogen activator gene by cytoskeleton-disrupting agents. In: Festoff B W (ed) Serine proteases and their serpin inhibitors in the nervous system. Plenum Press, New York, 1990; 105-114.
131. Declercq P, Carmeliet P, Verstreken M, Decock F, Collen D. Monoclonal antibodies raised against the targeted proteins in gene-inactivated mice. J Biol Chem 1995; 270: 8397-8400.